Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Phosphorylation of Parkin at serine 65 is essential for its activation in vivo.

McWilliams TG, Barini E, Pohjolan-Pirhonen R, Brooks SP, Singh F, Burel S, Balk K, Kumar A, Montava-Garriga L, Prescott AR, Hassoun SM, Mouton-Liger F, Ball G, Hills R, Knebel A, Ulusoy A, Di Monte DA, Tamjar J, Antico O, Fears K, Smith L, Brambilla R, Palin E, Valori M, Eerola-Rautio J, Tienari P, Corti O, Dunnett SB, Ganley IG, Suomalainen A, Muqit MMK.

Open Biol. 2018 Nov 7;8(11). pii: 180108. doi: 10.1098/rsob.180108.

2.

Understanding optimization processes of electronic health records (EHR) in select leading hospitals: a qualitative study.

Moon MC, Hills R, Demiris G.

J Innov Health Inform. 2018 Jun 30;25(2):109-125. doi: 10.14236/jhi.v25i2.1011.

3.

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, Dillon R, Grimwade D; NCRI AML Working Group.

Blood. 2018 Sep 27;132(13):1452-1454. doi: 10.1182/blood-2018-05-851824. Epub 2018 Aug 10. No abstract available.

PMID:
30097508
4.

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6.

5.

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.

Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, Kjeldsen L, Hawkins T, Betteridge SE, Cahalin P, Clark RE, Hills RK, Russell NH; UK NCRI AML Study Group.

Haematologica. 2018 Oct;103(10):1654-1661. doi: 10.3324/haematol.2018.189514. Epub 2018 Jul 5.

6.

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Burnett AK, Hills RK, Nielsen OJ, Freeman S, Ali A, Cahalin P, Hunter A, Thomas IF, Russell NH.

Leukemia. 2018 Jun 6. doi: 10.1038/s41375-018-0148-3. [Epub ahead of print] No abstract available.

PMID:
29875430
7.

Will Rogers: actor, humourist … and ALL epidemiologist?

Hills R.

Br J Haematol. 2018 Sep;182(6):755. doi: 10.1111/bjh.15423. Epub 2018 May 29. No abstract available.

PMID:
29808914
8.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Lucas CM, Scott LJ, Carmell N, Holcroft AK, Hills RK, Burnett AK, Clark RE.

Blood Adv. 2018 May 8;2(9):964-968. doi: 10.1182/bloodadvances.2017013615. No abstract available.

9.

Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods.

Parkinson C, Foley K, Whybra P, Hills R, Roberts A, Marshall C, Staffurth J, Spezi E.

EJNMMI Res. 2018 Apr 11;8(1):29. doi: 10.1186/s13550-018-0379-3.

10.

Fatal and non-fatal overdose among opiate users in South Wales: A qualitative study of peer responses.

Holloway K, Hills R, May T.

Int J Drug Policy. 2018 Jun;56:56-63. doi: 10.1016/j.drugpo.2018.03.007. Epub 2018 Apr 17.

PMID:
29605706
11.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.

J Clin Oncol. 2018 May 20;36(15):1486-1497. doi: 10.1200/JCO.2017.76.3425. Epub 2018 Mar 30.

12.

Cultural competence in healthcare in the community: A concept analysis.

Henderson S, Horne M, Hills R, Kendall E.

Health Soc Care Community. 2018 Jul;26(4):590-603. doi: 10.1111/hsc.12556. Epub 2018 Mar 7.

PMID:
29516554
13.

Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.

Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, Cook A, Gattamaneni R, Jain R, Olver J, Hurel SJ, Bremner F, Drummond SR, Kemp E, Ritchie DM, Rumsey N, Morris D, Lane C, Palaniappan N, Li C, Pell J, Hills R, Ezra DG, Potts MJ, Jackson S, Rose GE, Plowman N, Bunce C, Uddin JM, Lee RWJ, Dayan CM.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):299-309. doi: 10.1016/S2213-8587(18)30021-4. Epub 2018 Jan 31.

PMID:
29396245
14.

Refining amino acid hydrophobicity for dynamics simulation of membrane proteins.

Hills RD Jr.

PeerJ. 2018 Jan 10;6:e4230. doi: 10.7717/peerj.4230. eCollection 2018.

15.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

PMID:
29330221
16.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK, Russell NH, Hills RK, Linch DC.

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11. No abstract available.

PMID:
29229596
17.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D.

Blood. 2018 Feb 8;131(6):636-648. doi: 10.1182/blood-2017-07-794784. Epub 2017 Nov 30.

18.

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.

El-Sharkawi D, Sproul D, Allen CG, Feber A, Wright M, Hills RK, Linch DC, Gale RE.

Haematologica. 2018 Jan;103(1):91-100. doi: 10.3324/haematol.2017.173096. Epub 2017 Oct 12.

19.

Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Wright M, Hills R, Gallimore A, Godkin A.

JAMA Oncol. 2017 Oct 12;3(10):e172579. doi: 10.1001/jamaoncol.2017.2579. Epub 2017 Oct 12.

20.

Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer.

Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Hills R, Gallimore A, Godkin A.

Clin Cancer Res. 2017 Nov 15;23(22):6771-6780. doi: 10.1158/1078-0432.CCR-17-0895. Epub 2017 Aug 29.

21.

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.

Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, Heck S, Yang JHM, Tree TIM, Pujol-Autonell I, Yeo L, Baumard LR, Stenson R, Howell A, Clark A, Boult Z, Powrie J, Adams L, Wong FS, Luzio S, Dunseath G, Green K, O'Keefe A, Bayly G, Thorogood N, Andrews R, Leech N, Joseph F, Nair S, Seal S, Cheung H, Beam C, Hills R, Peakman M, Dayan CM.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaaf7779. doi: 10.1126/scitranslmed.aaf7779.

PMID:
28794283
22.

Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer.

Foley KG, Hills RK, Berthon B, Marshall C, Parkinson C, Lewis WG, Crosby TDL, Spezi E, Roberts SA.

Eur Radiol. 2018 Jan;28(1):428-436. doi: 10.1007/s00330-017-4973-y. Epub 2017 Aug 2.

23.

Completeness and timeliness of notifiable disease reporting: a comparison of laboratory and provider reports submitted to a large county health department.

Dixon BE, Zhang Z, Lai PTS, Kirbiyik U, Williams J, Hills R, Revere D, Gibson PJ, Grannis SJ.

BMC Med Inform Decis Mak. 2017 Jun 23;17(1):87. doi: 10.1186/s12911-017-0491-8.

24.

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.

Tiong IS, Tan P, McManus J, Cummings N, Sadawarte S, Catalano J, Hills R, Wei A.

Leuk Lymphoma. 2018 Feb;59(2):493-496. doi: 10.1080/10428194.2017.1334122. Epub 2017 Jun 8. No abstract available.

PMID:
28592158
25.

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

Williams J, Heppel NH, Britt-Compton B, Grimstead JW, Jones RE, Tauro S, Bowen DT, Knapper S, Groves M, Hills RK, Pepper C, Baird DM, Fegan C.

Br J Haematol. 2017 Jul;178(2):240-249. doi: 10.1111/bjh.14666. Epub 2017 May 9.

PMID:
28486748
26.

Structural and functional analysis of the human POT1-TPP1 telomeric complex.

Rice C, Shastrula PK, Kossenkov AV, Hills R, Baird DM, Showe LC, Doukov T, Janicki S, Skordalakes E.

Nat Commun. 2017 Apr 10;8:14928. doi: 10.1038/ncomms14928.

27.

Telomere length is a critical determinant for survival in multiple myeloma.

Hyatt S, Jones RE, Heppel NH, Grimstead JW, Fegan C, Jackson GH, Hills R, Allan JM, Pratt G, Pepper C, Baird DM.

Br J Haematol. 2017 Jul;178(1):94-98. doi: 10.1111/bjh.14643. Epub 2017 Mar 24.

PMID:
28342200
28.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

29.

Notifiable condition reporting practices: implications for public health agency participation in a health information exchange.

Revere D, Hills RH, Dixon BE, Gibson PJ, Grannis SJ.

BMC Public Health. 2017 Mar 11;17(1):247. doi: 10.1186/s12889-017-4156-4.

30.

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia.

Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK.

Leukemia. 2017 May;31(5):1234-1237. doi: 10.1038/leu.2017.37. Epub 2017 Jan 23. No abstract available.

PMID:
28111469
31.

BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.

Chen HS, De Leo A, Wang Z, Kerekovic A, Hills R, Lieberman PM.

PLoS Pathog. 2017 Jan 20;13(1):e1006100. doi: 10.1371/journal.ppat.1006100. eCollection 2017 Jan.

32.

Non-inferiority trials: No better? No worse? No change? No pain?

Hills RK.

Br J Haematol. 2017 Mar;176(6):883-887. doi: 10.1111/bjh.14504. Epub 2017 Jan 20. Review.

PMID:
28106905
33.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

34.

Statistical reporting in the BJH: some dos and don'ts.

Hills RK.

Br J Haematol. 2017 Feb;176(3):345-351. doi: 10.1111/bjh.14426. Epub 2016 Nov 18. Review.

PMID:
27859002
35.

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities.

Chilton L, Hills RK, Burnett AK, Harrison CJ.

Leukemia. 2016 Nov;30(11):2264-2267. doi: 10.1038/leu.2016.200. Epub 2016 Jul 25. No abstract available.

36.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.

37.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

38.

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.

Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K.

Blood. 2016 Dec 15;128(24):2819-2823. Epub 2016 Oct 19.

39.

Treatment intensification in diffuse large B-Cell lymphoma: lessons for clinical trial design.

Hills RK.

Br J Haematol. 2016 Nov;175(4):555-556. doi: 10.1111/bjh.14400. Epub 2016 Oct 13. No abstract available.

PMID:
27734467
40.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

41.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE.

Leukemia. 2017 Feb;31(2):310-317. doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

42.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.

43.

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.

Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group.

Blood. 2016 Jul 21;128(3):449-52. doi: 10.1182/blood-2016-04-712091. Epub 2016 Jun 6. No abstract available.

44.

Communication Capacity Building through Pharmacy Practice Simulation.

Fejzic J, Barker M, Hills R, Priddle A.

Am J Pharm Educ. 2016 Mar 25;80(2):28. doi: 10.5688/ajpe80228.

45.

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A, Estey E.

Haematologica. 2016 Jul;101(7):e284-6. doi: 10.3324/haematol.2015.138552. Epub 2016 Mar 24. No abstract available.

46.

The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.

Zabkiewicz J, Gilmour M, Hills R, Vyas P, Bone E, Davidson A, Burnett A, Knapper S.

Oncotarget. 2016 Mar 29;7(13):16650-62. doi: 10.18632/oncotarget.7692.

47.

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.

Burnett A, Cavenagh J, Russell N, Hills R, Kell J, Jones G, Nielsen OJ, Khwaja A, Thomas I, Clark R; UK NCRI AML Study Group.

Haematologica. 2016 Jun;101(6):724-31. doi: 10.3324/haematol.2016.141937. Epub 2016 Feb 26.

48.

Model parameters for simulation of physiological lipids.

Hills RD Jr, McGlinchey N.

J Comput Chem. 2016 May 5;37(12):1112-8. doi: 10.1002/jcc.24324. Epub 2016 Feb 11.

49.

The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.

Dickson GJ, Bustraan S, Hills RK, Ali A, Goldstone AH, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2016 Feb;172(4):573-80. doi: 10.1111/bjh.13873. Epub 2015 Dec 21.

50.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group.

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

Supplemental Content

Support Center